Methoxphenidine
Viewing r1 — May 3, 2026 — CURRENT
Back to HistoryInteractions, related substances, and reports reflect the current entry and are not shown for historical revisions.
MXP (methoxphenidine) is a synthetic dissociative of the diarylethylamine class. It is a structural analog of diphenidine, but produces a longer experience and has no direct dopamine-releasing activity.[1] MXP blocks glutamate signaling in the brain, disrupting how information is integrated — producing the cognitive and perceptual detachment characteristic of dissociatives.[2]
Psychedex is in open beta. We are still fine-tuning the generation and review process. Please double-check sources.
First described in a 1989 pharmaceutical patent for treating neurotoxic brain injury, MXP was never advanced to clinical trials.[3] It entered recreational markets in 2013 as a legal substitute for ketamine and methoxetamine after UK restrictions targeted related compounds.[4] MXP is now controlled in the UK, Canada, France, and several other countries.
Subjective effects include cognitive disconnection, derealization, spatial disorientation, visual suppression, and alternating waves of stimulant-like energy and heavy sedation.[4] The experience is defined by its unpredictable, biphasic character — energy and heaviness cycling in ways that shift decisively toward immobility at higher doses. The onset is slow, which invites accidental redosing;[5] anxiety, agitation, confusion, and seizures are all documented unwanted effects.
Physical dependence can develop after short periods of heavy use,[6] and 31 UK deaths have been linked to MXP.[7] Street samples frequently contain synthesis impurities that dramatically amplify toxicity beyond what the compound itself produces,[8] and most deaths involved other substances. No controlled human study has been conducted — the evidence rests on animal pharmacology, forensic cases, and user accounts.
History[edit]
Discovery
Methoxphenidine was first described in a 1989 patent by Nancy M. Gray and Brian K. Cheng of G.D. Searle & Co., covering treatment of neurotoxic brain injury using 1,2-diarylethylamines.[9][3] It was never advanced to clinical trials. The broader diarylethylamine class had roots in the 1940s, with related compounds later studied as experimental treatments for brain injury.[2][10]
Emergence and market trajectory
MXP appeared on research chemical markets in 2013, sold explicitly as a legal alternative to methoxetamine and ketamine after UK restrictions targeted related dissociatives.[4][9] The first documented clinical toxicity case appeared in 2014,[9] the first fatalities in 2015,[11] with cases peaking around 2016.[12]
Regulatory response
The UK Advisory Council on the Misuse of Drugs published its review of diarylethylamines in 2023 and recommended Class B scheduling.[6] MXP became a Class B, Schedule 1 substance in the UK on 20 March 2024.[13] International scheduling bodies reviewed MXP in 2020–2021 but chose not to add it to UN drug conventions, placing it under continuing surveillance instead.[6]
The abbreviation MXP (sometimes 2-MXP or 2-MeO-diphenidine) marks its position as the 2-methoxy-substituted variant of diphenidine. The "2-" prefix distinguishes it from positional isomers 3-MXP and 4-MXP, which carry different pharmacological profiles.[14] MXP's market identity was shaped entirely by regulatory displacement — it arrived not on its own merits but as a substitute for controlled compounds, a pattern common among novel psychoactive substances.
Chemistry[edit]
Structural class
MXP (methoxphenidine) belongs to the diarylethylamine structural family — compounds built around a two-carbon chain linking two aromatic rings with an amine group. It is a direct structural analog of diphenidine, distinguished by the addition of a methoxy group at one aromatic ring.[14][2]
Its molecular formula is C₂₀H₂₅NO (molecular weight 295.4 g/mol). Three positional isomers exist — 2-MXP, 3-MXP, and 4-MXP — with different pharmacological profiles; the 2-isomer is most commonly encountered.[14]
Pharmacology[edit]
Mechanism of action
MXP blocks glutamate signaling by locking the NMDA's ion channel closed, preferentially targeting active neurons.[2][6] This places it in the same potency range as ketamine.
Unlike its close relative diphenidine, MXP does not directly trigger dopamine release.[1] It still activates the brain's reward system — but indirectly, by releasing an inhibitory brake on dopamine-producing neurons through glutamate blockade, rather than through direct reuptake blockade.[15]
Pharmacokinetics
No human pharmacokinetic data exist for MXP. In rats, it rapidly crosses into the brain and concentrates there at levels roughly eight times higher than in blood.[16][17] The body breaks MXP down primarily by removing its methoxy group,[17][11] producing a metabolite that persists in brain tissue longer than the parent compound.[17]
Neuroscience[edit]
Where it acts
MXP's dissociative effects arise from blocking glutamate signaling across cortical and subcortical brain networks. This silences inhibitory neurons in the cortex — paradoxically increasing overall brain activity while disrupting the organized flow of signals between regions.[2] The brain keeps generating activity but stops integrating it coherently. That breakdown is the dissociative state.
Why it matters
MXP triggers dopamine release in the brain's reward center without directly blocking dopamine reuptake. Instead, blocking glutamate signaling releases an inhibitory brake on dopamine-producing neurons.[1][15] This indirect mechanism produces both the reinforcing properties that drive repeated use and the behavioral disruptions — social withdrawal, cognitive impairment — seen in animal models.[15]
Subjective Effects[edit]
The MXP experience is defined by its unpredictability. Rather than a smooth arc, it moves in waves — periods of stimulant-like energy alternating with heavy dissociative sedation.[4] A slow onset creates a deceptive window where the full effects have not yet arrived, masking how much has already been taken.[5]
Compared to ketamine, MXP produces a longer, less controllable dissociative experience with more stimulant character at lower doses. Compared to diphenidine, it is less euphoric — consistent with its lack of direct dopamine activity[1] — but longer-lasting and with a slower, less predictable resolution.
Effect Grid
At common doses (75–120 mg oral), the full dissociative experience manifests. Cognitive disconnection deepens into pronounced derealization and depersonalization. Spatial disorientation becomes significant — navigation of physical space requires deliberate effort. Visual processing suppression is evident: double vision, reduced visual acuity, and flattened depth perception. Amnesia for portions of the experience is common. The biphasic stimulant-sedative wave pattern reported by users is most apparent at this range.
Physically, hypertension and tachycardia are expected based on clinical intoxication data. Body feels heavy or numb. Motor coordination is substantially impaired, and speech may become slurred or difficult.
Duration is 6–8 hours with 1–3 hours of aftereffects. Functional impairment persists well beyond the subjective peak. Planning for an extended time commitment is essential.
Modeled from the effect's dose-dependence curve — not per-substance measurements.
Sensory deprivation · Touch suppression · Music enhancement · Visual acuity suppression · Depth perception distortion · Auditory distortion · Auditory suppression · Visual haze / noise · Dreaming enhancement · Tracers · Visual drifting · Tinnitus · Visual processing suppression · Internal hallucinations · External hallucinations · Environmental orbism / cubism · Visual scenery slicing · Auditory hallucinations
Depth perception distortion · Auditory distortion · Auditory suppression · Visual haze / noise · Dreaming enhancement · Tracers · Visual drifting · Tinnitus · Visual processing suppression · Internal hallucinations · External hallucinations · Environmental orbism / cubism · Visual scenery slicing · Auditory hallucinations
Sedation · Bodily lightness · Body high · Body schema distortion · Spontaneous body sensations · Bodily heaviness · Muscle relaxation · Pupil dilation · Tingling / electric sensations · Sexual arousal suppression · Heart rate perception changes · Laughter fits · Nausea · Tactile euphoria · Vibrations / buzzing · Stimulation · Motor control enhancement · Bodily dissociation
Spontaneous body sensations · Bodily heaviness · Muscle relaxation · Pupil dilation · Tingling / electric sensations · Sexual arousal suppression · Heart rate perception changes · Laughter fits · Nausea · Tactile euphoria · Vibrations / buzzing · Stimulation · Motor control enhancement · Bodily dissociation
Information processing suppression · Thought deceleration · Analysis suppression · Cognitive euphoria · Focus suppression · Memory fragmentation · Thought disorganization · Pattern recognition suppression · Cognitive fatigue · Humor enhancement · Conceptual thinking · Cognitive dysphoria · Compulsive redosing urge · Immersion enhancement · Introspection enhancement · Language suppression · Thought loops · Thought acceleration · Delusions of sobriety · Creativity enhancement · Amnesia · Delirium
Cognitive euphoria · Focus suppression · Memory fragmentation · Thought disorganization · Pattern recognition suppression · Cognitive fatigue · Humor enhancement · Conceptual thinking · Cognitive dysphoria · Immersion enhancement · Introspection enhancement · Language suppression · Thought loops · Thought acceleration · Delusions of sobriety · Creativity enhancement · Amnesia · Delirium
Emotional lability · Empathy suppression · Dysphoria
Sociability suppression · Social disconnection · Craving · Cognitive disconnection · Boundary dissolution · Ego dissolution · Identity alteration
Boundary dissolution · Ego dissolution · Identity alteration
Timeline
First alerts emerge 30–60 minutes after ingestion: a subtle shift in spatial awareness, mild light-headedness, and faint cognitive slowing. The slow onset is a distinctive feature of oral MXP and a primary driver of accidental redosing.
Dissociative effects build steadily over 30–60 minutes. Spatial disorientation, visual dulling, and cognitive disconnection become progressively more apparent. A stimulant-like energy wave is common during this phase.
Maximum dissociative intensity sustained for 2–3 hours. Derealization, depersonalization, and visual processing suppression dominate. Motor coordination is significantly impaired.
Effects plateau at moderate intensity for 1. 5–2 hours. Dissociation remains present but the acute peak subsides.
Gradual return toward baseline over 1–1. 5 hours. Dissociative effects fade but residual spatial disorientation, cognitive fog, and mild derealization persist.
Residual effects lasting 1–3 hours: mild cognitive haze, emotional blunting or subtle mood elevation, and lingering fatigue. Some users report a sense of empowerment or clarity during this phase.
⚠ Do not drive or operate machinery until the following day, as residual dissociative impairment and slowed reaction times may persist beyond subjective awareness.
Safety[edit]
- Acute toxicity
- High
- Chronic toxicity
- Moderate
- Withdrawal
- Mild
- Tolerance buildup
- moderate
- Tolerance reset
- 10 days
- Physical
- Moderate
- Psychological
- Moderate
- Compulsive redosing
- Moderate
- Dose escalation
- Moderate
- Cross-tol.
- dissociatives
Toxicity
Acute toxicity
No lethal dose has been established in humans. Post-mortem blood concentrations in fatal cases span a wide range (1.36–24.0 mg/L),[11] making it impossible to identify a reliable dangerous threshold — individual variation and polydrug use confound the picture.
Fatalities
Multiple deaths have been documented. A systematic review found 31 UK deaths involving MXP alone or in combination, with 14 attributed primarily to MXP.[7] Those who died were predominantly male (91%), average age 37; most deaths occurred 2014–2016. Eight additional deaths were documented in Japan and the US.[7]
Heart and circulation
Elevated blood pressure occurs in 76% of documented MXP intoxication cases, and rapid heart rate in 47%.[18][12] These are the most consistent clinical findings in intoxication cases.
Street sample contamination
Street samples of MXP have been found to contain zinc halide synthesis impurities that dramatically increase cellular toxicity across kidney, liver, and bladder tissue.[8] Standard reagent tests — Mecke, Marquis, Mandelin — and common analytical methods do not detect them.[8]
Organ toxicity
There is currently no documented link between MXP and the kidney, bladder, and urinary tract damage associated with chronic ketamine use.[6] This reflects an absence of reported cases, not systematic investigation.
Psychological Risks
Anxiety and agitation occur in approximately 65% of clinical intoxication presentations.[18] Hallucinations, confusion, and psychotic symptoms are also documented.[18][12] Nearly half of confirmed intoxications were classified as severe.[18]
User reports describe chronic effects including long-term memory loss and limb numbness.[4] Animal studies show social withdrawal, depression-like behavior, and cognitive impairment.[15] The frequency of lasting perceptual disturbances or persistent psychosis following MXP use has not been studied.
Tolerance & Dependence
Tolerance develops with repeated MXP use. Community estimates place the half-life of tolerance at approximately 5 days, with full reset at about 1.5 weeks, and cross-tolerance to other dissociatives.inferred
Physical dependence is documented. One case described a 21-year-old who developed abdominal pain, vomiting, and low-grade fever after only weeks of use.[6] The first documented MXP use disorder was reported to the French Addictovigilance Network.[19]
Drug Interactions
No MXP-specific interaction studies have been published. The following risks are inferred from pharmacological class and clinical co-ingestion data.
CNS depressants (alcohol, opioids, GHB, benzodiazepines): MXP alone causes significant altered mental status. Adding any CNS depressant compounds sedation and breathing risk. Multiple fatalities involved co-ingestion of other substances.[11][12]inferred
Stimulants (cocaine, amphetamines, cathinones): MXP already raises blood pressure and heart rate.[18][12] Stimulants amplify this cardiovascular strain.[4]inferred
MAOIs: No data exist. MXP has minimal SERT activity,[2] but can modulate serotonin systems indirectly. Treat as high-risk.safety citation needed
Serotonergic drugs: MXP's minimal serotonin activity substantially reduces serotonin syndrome risk compared to compounds like dxm.[2] Indirect serotonergic effects cannot be fully excluded.inferred
CYP-mediated interactions: Potent inhibitors of the liver enzymes that metabolize MXP could theoretically raise MXP blood levels. No MXP-specific data exist.inferred
Contraindications
No substance-specific contraindication studies exist. The following are inferred from clinical data and pharmacological class.
Pre-existing high blood pressure or heart conditions: Elevated blood pressure and rapid heart rate are the most frequent clinical findings in MXP intoxication — 76% and 47% of cases respectively.[18]inferred
Psychotic disorders or active psychosis: MXP produces hallucinations and psychotic symptoms[18][12] and triggers schizophrenia-like behavioral changes in animal models.[15]inferred
Seizure disorders: Seizures have been reported in user accounts and clinical cases.[4][12]inferred
Liver impairment: MXP is primarily metabolized by the liver. Impaired liver function reduces clearance and increases systemic exposure.inferred
Pregnancy and breastfeeding: No reproductive toxicology data exist. Use is contraindicated by precautionary principle.inferred
Harm Reduction[edit]
Forms & Identification
MXP typically appears as a white to off-white powder or crystalline solid. The three positional isomers — 2-MXP, 3-MXP, 4-MXP — look identical to the eye and share similar basic analytical profiles, but have different pharmacological effects.[14] Only laboratory-grade testing can confirm which isomer is present.
Street samples have been found to contain zinc halide synthesis impurities that dramatically increase cellular toxicity.[8] Standard reagent tests — Mecke, Marquis, Mandelin — and common analytical methods do not detect them.[8] Sourcing from vendors with third-party analytical verification reduces but does not eliminate this risk.
Guidelines
- Test every batch with reagent kits and, where available, quantitative analysis — reagent tests alone cannot detect zinc halide impurities[8]
- Start at the low end of the dose range, especially with untested material or new batches
- Do not redose during the first 90 minutes — the slow onset creates a deceptive window that drives accidental overdose[5]
- Have a sober sitter present for the full duration
- Keep the environment controlled — remove access to heights, water, roads, and sharp objects before onset
- Pre-arrange a 24-hour window with no obligations — the experience is long and aftereffects can persist
- Stay hydrated but avoid alcohol
Set & Setting
MXP's extended duration and unpredictable biphasic character require planning.[4] The experience alternates between stimulant-like energy and heavy dissociative sedation — poorly suited to environments requiring mobility, social coherence, or fast decisions.
A sober, trusted sitter is strongly recommended, especially at higher doses. Prior dissociative experience and current tolerance significantly shape the experience.[5] A familiar, controlled, low-stimulation environment is optimal.
Aftercare & integration. The extended duration and cognitive disruption of MXP mean recovery requires time. Allow at least 24 hours of low-demand activity after the acute effects resolve. Sleep may be difficult in the hours following the experience — this is expected and typically resolves within a day.
Dissociative experiences can leave residual feelings of unreality or detachment that may persist for hours to days. Grounding practices — physical activity, structured routine, social contact, time outdoors — help re-establish a normal sense of embodiment. If feelings of unreality, memory difficulty, or emotional flatness persist beyond a few days, consult a healthcare provider.
Recovery & Support
Physical dependence on MXP can develop after relatively short periods of heavy use.[6] Withdrawal symptoms including abdominal pain, vomiting, and fever have been documented. Anyone experiencing difficulty controlling use or withdrawal symptoms when stopping should seek medical support.
Dissociative use disorders are recognized in addiction medicine. SAMHSA's National Helpline (1-800-662-4357) provides free, confidential treatment referrals. For those outside the US, national addiction services or a general practitioner can provide referrals to appropriate care.
Recovery resources, crisis lines, and support pathways → View all
Emergency Response
Recognizing an emergency: MXP intoxication becomes a medical emergency when any of the following occur: seizure, loss of consciousness with no response to loud voice or sternal rub, difficulty breathing, chest pain, body temperature that feels extremely hot through clothing, or severe agitation with risk of self-harm.
Immediate steps:
- 1. Call emergency services immediately
- 2. Place an unconscious but breathing person in the recovery position (on their side, airway clear)
- 3. Do not restrain an agitated person unless they are in immediate physical danger — restraint can escalate the situation
- 4. Monitor breathing continuously until help arrives
- 5. Do not induce vomiting
What to tell the dispatcher: Name the substance (methoxphenidine / MXP), the approximate amount taken, the time of ingestion, and current symptoms. Good Samaritan laws in many jurisdictions protect callers from drug-related prosecution. No reversal agent exists for MXP — treatment is supportive.
Legal Status[edit]
Methoxphenidine's legal status varies by country and has changed rapidly in recent years.
| Jurisdiction | Classification | Key provisions |
|---|---|---|
| United Kingdom | Class B, Schedule 1 (Misuse of Drugs Act 1971) | Controlled since 20 March 2024 via SI 2024/190. Possession: max 5 years. Supply/production: max 14 years. Research requires Home Office licence. Previously covered by Psychoactive Substances Act 2016 from May 2016.[13] |
| Canada | Schedule I (CDSA) | Possession without authority: max 7 years imprisonment.[6] |
| Australia | Schedule 9 (Prohibited substance, SUSMP) | Effective 1 October 2024. Research use only with permit. |
| France | Narcotic drug (Annex IV) | Classified under French drug control regulations. Exact scheduling date unconfirmed.[12] |
| China | Controlled substance | Controlled from September 2015.[6] |
| Italy | Controlled substance | Controlled from August 2016.[6] |
| Sweden | Controlled substance | Controlled; date not confirmed.[6] |
| Denmark | Controlled substance | Controlled; date not confirmed.[6] |
| Japan | Designated Substance | Listed on Designated Substance list; exact date not confirmed.[6] |
| United States | Not specifically scheduled (CSA) | Not scheduled under the Controlled Substances Act as of the most recent confirmed information. Potentially covered by the Federal Analogue Act (21 U.S.C. § 813) if intended for human consumption and shown to be substantially similar to a Schedule I/II substance. No formal DEA scheduling action confirmed. safety citation needed |
Legal status changes frequently and varies within jurisdictions. The information above reflects the most recently confirmed data available and is not legal advice. Verify current status with local legal resources before drawing any conclusions.
references
- [1] ^abcdSahai MA, Davidson C, Dutta N, Opacka-Juffry J (2018) Mechanistic Insights into the Stimulant Properties of Novel Psychoactive Substances (NPS) and Their Discrimination by the Dopamine Transporter-In Silico and In Vitro Exploration of Dissociative Diarylethylamines — Brain Sciences doi:10.3390/brainsci8040063
- [2]
- [3]
- [4]
- [5] ^abcdHearne E, Van Hout MC (2016) "Trip-Sitting" in the Black Hole: A Netnographic Study of Dissociation and Indigenous Harm Reduction — Journal of Psychoactive Drugs doi:10.1080/02791072.2016.1207827
- [6]